HDAC9 and thyroid cancer, nonmedullary, 2: Whether this represents a pathway specific to the invasion machinery itself or an adaptation to new non-tumorous surrounding tissue remains to be seen, but the availability of novel HDAC inhibitor drugs (currently in use for some hematologic malignancies) could present an intriguing possibility for patients with metastatic or even high-risk localized FTC, if these results can be further validated in vitro and in vivo.